Q-omics provides the consensus-scored VMO1 profile across patient tissues and cancer cell-line models. VMO1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VMO1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, VMO1 RNA expression shows 14,666 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where VMO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VMO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VMO1 survival associations across molecular data types. VMO1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VMO1 RNA expression–survival associations across cancer types. High VMO1 expression shows unfavorable associations in KIRC, ACC and PRAD, but favorable associations in SKCM, LUAD and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VMO1 RNA expression.
This table summarizes VMO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for VMO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VMO1 shows lower tumor expression in LUSC, LUAD and KICH and higher tumor expression in KIRC, STAD and KIRP. The KIRC box plot shows higher VMO1 RNA expression in tumor versus normal tissue (log2 FC = +1.070, t-test p < 0.001).
This table shows molecular features associated with VMO1 in patient tissues and cancer cell lines. In patient samples, VMO1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, VMO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
